AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: tDCS
Description: All participants randomized to tDCS will receive active tDCS
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will exercise at Toronto Rehab.
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will exercise at Toronto Rehab.
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham stimulation
Description: The same procedure for tDCS will be used for the sham condition, except without active current.
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Exercise education/ treatment as usual will include routine advice about physical activity.
Study NCT05576350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Based Alcohol Monitoring (SAM)
Description: Smartphone-based alcohol monitoring (SAM) using mobile breathalyzers and surveys.
Study NCT05576350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking and Reducing Alcohol Consumption (TRAC)
Description: The TRAC intervention focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage drinking. It requires four 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the four sessions of intervention content, participants will complete smartphone-based self-monitoring of alcohol consumption, which will be discussed during intervention sessions.
Study NCT05576350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAC-ER
Description: Ecological momentary interventions (EMI) use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use.
Study NCT06205095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
Description: Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
Study NCT06205095 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
Study NCT05347914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be taught a mindfulness exercise and will be instructed to use this exercise (following a mobile app) whenever they experience a food craving to eat for non-homeostatic reasons.
Study NCT05927246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: 12 lead ecg for each participant
Study NCT03988439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-118 Lotion
Description: Topical
Study NCT05035641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: Orally, 3 times per week in Period 1 and randomize to TIW or QW group at the same dose in Period 2
Study NCT05418790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TASSO device
Description: During this trial, participants will have approximately 15 TASSO collection dates between in clinic and at home.
Study NCT05035641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, 3 times per week
Study NCT04916782 — intervention group
Intervention type: OTHER
Intervention: Quality of life Questionnaire
Description: Quality of life questionnaire
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate Injection
Description: Weight ≥ 10 kg: 20 g/m2/dose STS or Weight 5-10 kg: 15 g/m2/dose STS or Weight \< 5 kg: 10 g/m2/dose STS will be administered by IV over 2 hours beginning 6 hours after the completion of each cisplatin infusion.
Study NCT04478292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary surgery resection
Description: Resection of the primary tumor up-front
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mono CDDP-Group A2
Description: Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy. Each cycle lasts 3 weeks (21 days).
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-Fluorouracil, Vincristine, Doxorubicin-Group C
Description: All the patients in Group C (2 arms) will receive 6 cycles chemotherapy in total. Cisplatin 100 mg/m2/dose Day 1; 5-Fluorouracil 600 mg/m2/dose Day 1; Vincristine 1.5 mg/m2/dose Day 1,8 and 15; Doxorubicin 30 mg/m2/dose Day 1 and 2; (Dexrazoxane : 300 mg/m2/dose Day 1 and 2, where is available)
Study NCT04478292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Tumors are deemed unresectable at diagnosis.
Study NCT05103644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: patients received statin experimental group
Study NCT04478292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection or transplant
Description: Ideal timing to resect of the primary tumors or transplant if if excellent response achieved at 1st or 2nd evaluation timepoint. But surgery timing is not mandated. Irrespective of the timing of surgery, patients should complete all planned protocol cycles of chemotherapy (including post transplantation). If surgical resection of the primary tumor is delayed until the end of therapy, no further post-operative chemotherapy should be given.
Study NCT04478292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection of pulmonary nodules
Description: Resection of pulmonary nodules should be considered in Group D2, patients at any cycle if continuing to respond to consolidation therapy.
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mono CDDP- Group B
Description: Cisplatin 80 mg/m2/dose Day 1. All patients in Group B (2 arms) will receive 6 cycles of mono cisplatin chemotherapy. Each cycle lasts 2 weeks (14 days).
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Block 1 to 3 (Cisplatin, Doxorubicin) Group D
Description: Block 1 and 2: Cisplatin 70 mg/m2/dose Day1, 8 and 15; Doxorubicin 30 mg/m2/dose, Day 8 and 9; (Dexrazoxane: 300 mg/m2/dose Day 1 and 2, where is available); Block 3: Cisplatin 70 mg/m2/dose Day1and 8; Doxorubicin 30 mg/m2/dose Day 8 and 9; (Dexrazoxane BSA ≥ 0.6 m2/dose: 300 mg/m2/dose Day 8 and 9, where is available) All patients in Group D will receive 3 blocks in induction, followed by consolidation therapy. Block 1 and 2 last 28 days. Block 3 is 21 cycles.
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation (Carboplatin, Doxorubicin) -Group D1
Description: Following Block 1-3 of induction therapy, Group D1 patients will receive 3 cycles of Carboplatin + Doxorubicin consolidation therapy. Each cycle lasts 3 weeks (21 days). Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).
Study NCT04478292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation (Carboplatin +Doxorubicin/Vincristine + Irinotecan)-Group D2
Description: Following Block 1-3 of induction therapy, patients in Group D2, will receive 6 cycles of consolidation chemotherapy with Carboplatin + Doxorubicin in Cycles 1, 3, and 5 alternating with Vincristine + irinotecan in Cycles 2, 4, and 6. One cycle of therapy lasts 3 weeks (21 days). Cycle 1, 3 and 5: Carboplatin 500 mg/m2/dose Day 1; Doxorubicin 20 mg/m2/dose Day 1 and 2; (Dexrazoxane: 200 mg/m2/dose Day 1 and 2, where is available).~Cycle 2, 4 and 6: Vincristine 1.5 mg/m2/dose, Day 1 and 8; Irinotecan 50 mg/m2/dose, Day 1 to 5;
Study NCT05103644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received placebo control group
Study NCT06109116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self myofascial release+ Conventional PT
Description: The participant will be asked to sit on a chair and feet resting on the ground. A tennis ball is used on the sole of each foot behind the metatarsal heads to the heel Conventional PT including Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise concentrating on the medial arch for 2 minutes in sitting position,with as much pressure as they could, pushing into discomfort but not pain Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 35 mins Type: Self myofascial release to improve hamstring flexibility
Study NCT06109116 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional PT
Description: Hot pack,Knee to chest exercise, Bridging exercise, Straight leg raise exercise, Ankle pumping exercise, Superman position exercise .~Frequency: 3 times/week for 3 weeks Intensity: moderate intensity (pain free) Time: 30 mins
Study NCT05574166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-8356
Description: SP-8356 demonstrates anti-atherosclerotic and anti-ischaemic activity as a novel CD147 inhibitor.
Study NCT05574166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for SP-8356 powder
Study NCT05386823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF1K16
Description: HF1K16 for Injection doses will be calculated based on subject weight measured at admission, and diluted in sterile saline (0.9% sodium chloride). Doses will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Study NCT05386823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be sterile saline (0.9% sodium chloride) which will be administered using an IV infusion pump over a period of approximately 60 minutes at 2.5 mL/min.
Study NCT06142422 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: stimulation device
Description: The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation.
Study NCT04302389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myWW App, Virtual Workshops, and Private Facebook Group
Description: The 6-month intervention includes the use of WW's mobile app, weekly virtual workshops, and a private online community. Participants are given a personalized food plan based on expert healthy eating guidelines and the latest nutritional science, an activity plan designed to promote regular physical activity and techniques to help shift members towards a helpful mindset for lasting change all within the WW app. Participants will attend weekly virtual workshops led by an expert WW Coach. The coach will help with goal setting, overcoming setbacks, and follow-up on progress toward goals each week. Participants will be encouraged to participate in a private Facebook group that gives participants an opportunity to receive motivational support from each other. Participants can post about their journey through photos, videos, and comments.
Study NCT05424900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rethink game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
Study NCT05260970 — intervention group
Intervention type: PROCEDURE
Intervention: Rectus muscle reapproximation at cesarean section
Description: Rectus muscle reapproximation: Continuous Suturing of rectus muscles with 2.0 Vicryl (Ethicon) at Cesarean section.
Study NCT05086939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous MSCs
Description: Intra-articular injection 40 million/4 ml.
Study NCT06142422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stimulation device
Description: The procedure under study is the use of a stimulation device to perform treatment on the precuneus to treat resistant schizophrenia in patients exposed to childhood trauma.~The target is the left precuneus, which is defined by neuronavigation.
Study NCT05086939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic MSCs
Description: Intra-articular injection 40 million/4 ml.
Study NCT05086939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Intra-articular injection 60mg / 3 ml .
Study NCT06505629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the online Paired Emotion Reading Intervention (PERI)
Description: In the PERI, all children will receive three books about emotion knowledge. The paired reading groups will read and discuss these books over the next six weeks. Before starting the reading sessions, the paired groups will meet online via video to get to know each other and set reading goals. During the reading process, participants will check in daily with their reading progress. From the second week to the fifth week, participants will engage in weekly online discussions about the reading content. These discussions, led by the urban children, will follow a semi-structured discussion guide. The discussions aim to deepen the children's understanding of the book content and facilitate the application of emotion-related knowledge and emotion regulation strategies in their daily lives. The discussion sessions will be recorded and uploaded for regular review by the researchers.
Study NCT06505629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the online Paired General Reading Intervention (PGRI)
Description: Apart from the differences in the reading materials and discussion topics, all other aspects are identical to the PERI group. In the online PGRI, children will read three books of their choice, and discussions will center around general reading experiences and feelings.
Study NCT05983159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Oral alpha-specific PI3-kinase inhibitor
Study NCT04986540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1906；Placebo
Description: Drug: SHR-1906 IV, single dose~Drug: Placebo IV, single dose
Study NCT04996875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bezuclastinib
Description: Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
Study NCT06339047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Projector Kaleidoscope
Description: Children in the projector kaleidoscope group will be watched for approximately 5 minutes before induction in the operating room.
Study NCT06339047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Children in the cartoon group will be asked which cartoon they want to watch from the cartoon pool and will be shown the cartoon they want. The cartoon duration is approximately 5 minutes.
Study NCT04637035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Intervention entailing remote monitoring of patients' symptoms, vital signs, and body weight with home-based care.
Study NCT05657067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotionally Focused Family Therapy (EFFT)
Description: The rationale behind EFFT is that mental health problems in children and adolescents often originate and/or are exacerbated by negative interaction patterns rooted in insecure attachment bonds within families. Therefore, the main treatment goal of EFFT is the development of secure attachment between parents and their children.
Study NCT05514340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline along with standard treatment
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm normal saline along with standard treatment will be given for active comparison.
Study NCT05514340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sovateltide along with standard treatment
Description: Sovateltide is an endothelin-B receptor agonist. It has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in hypoxic-ischemic encephalopathy patients. In this arm sovateltide along with standard treatment will be given for active comparison.
Study NCT05757609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with active physiotherapy
Description: anodal tDCS over prefrontal cortex combined with active physiotherapy
Study NCT05757609 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham anodal tDCS combined with active physiotherapy
Description: Sham anodal tDCS over prefrontal cortex combined with active physiotherapy
Study NCT05734716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: use of erythropoietin to stimulate red blood cell development prior to ascent to altitude
Study NCT05734716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose (Venofer)
Description: use of iron sucrose to stimulate red blood cell development prior to ascent to altitude
Study NCT05734716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Sodium Chloride
Description: sham treatment with sterile saline
Study NCT06357741 — intervention group
Intervention type: DRUG
Intervention: Denosumab
Description: Desumumab, 60mg single injection
Study NCT06462495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-PSMA-N5
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Study NCT06462495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-PSMA-1007
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-1007, and undergo PET/CT imaging within the specificed time.
Study NCT05003882 — intervention group
Intervention type: OTHER
Intervention: Commercially available, orally ingestible CBD product
Description: botanically-derived CBD extract product
Study NCT06564818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYB003
Description: CYB003 is a synthetic psilocybin analog.
Study NCT06564818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitators
Study NCT06564818 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychological Support
Description: Manualized psychological support performed by facilitators
Study NCT06564818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05983159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: An investigational oral MEK inhibitor
Study NCT06339112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing with toy nebulizer
Description: The child who needs to take inhaler medication is taken to the observation room. Before starting the procedure, the toy nebulizer is introduced to the child. The toy nebulizer is shown to the child as an example and allowed to play, thus reducing the level of fear. Inhaler medication is given through a mask for 10 minutes. Vital signs (pulse) before and after the application. , blood pressure, SPo2, respiration), the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
Study NCT06339112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. 2-3 minutes before starting drug treatment, the child will be allowed to watch cartoons according to his age group and will be encouraged to do so throughout the procedure.~Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, the Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
Study NCT05257720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GFAP, S100B
Description: It is planned to measure serum GFAP and S100 B protein levels by ELISA method.
Study NCT05153226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
Study NCT05153226 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
Study NCT06171750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANK-101
Description: IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
Study NCT06171750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.